These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 33357606)
1. Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic. Dunn KE; Brooner RK; Stoller KB J Subst Abuse Treat; 2021 Feb; 121():108197. PubMed ID: 33357606 [TBL] [Abstract][Full Text] [Related]
2. Pilot investigation of an electronic pillbox at a community opioid treatment program. Sklar M; Doyle S; Kidorf M Am J Drug Alcohol Abuse; 2024 May; 50(3):328-333. PubMed ID: 38557232 [No Abstract] [Full Text] [Related]
3. Experience of patients on methadone maintenance treatment receiving take-home methadone doses during COVID-19 pandemic: A multi-site study from India. Kathiresan P; Patel V; Jangra J; Chattopadhyay A; Abdus S; Jadhav M; Rao R; Arya A; Bansal PD; Chinggouman C; Bhad R; Ambekar A; Agrawal A; Chatterjee B; Yadav D Asian J Psychiatr; 2024 May; 95():103979. PubMed ID: 38442535 [TBL] [Abstract][Full Text] [Related]
4. Use of an electronic pillbox to increase number of methadone take-home doses during the COVID-19 pandemic. Kidorf M; Brooner RK; Dunn KE; Peirce JM J Subst Abuse Treat; 2021 Jul; 126():108328. PubMed ID: 34116819 [TBL] [Abstract][Full Text] [Related]
5. Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19. Figgatt MC; Salazar Z; Day E; Vincent L; Dasgupta N J Subst Abuse Treat; 2021 Apr; 123():108276. PubMed ID: 33612201 [TBL] [Abstract][Full Text] [Related]
6. Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic. Hallgren KA; Darnton J; Soth S; Blalock KL; Michaels A; Grekin P; Saxon AJ; Woolworth S; Tsui JI J Subst Abuse Treat; 2022 Dec; 143():108896. PubMed ID: 36215911 [TBL] [Abstract][Full Text] [Related]
7. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership. Levander XA; Pytell JD; Stoller KB; Korthuis PT; Chander G Subst Abus; 2022; 43(1):633-639. PubMed ID: 34666636 [No Abstract] [Full Text] [Related]
8. Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis. Hoffman KA; Foot C; Levander XA; Cook R; Terashima JP; McIlveen JW; Korthuis PT; McCarty D J Subst Abuse Treat; 2022 Oct; 141():108801. PubMed ID: 35589443 [TBL] [Abstract][Full Text] [Related]
9. Opioid use and COVID-19: a secondary analysis of the impact of relaxation of methadone take-home dosing guidelines on use of illicit opioids. Panwala V; Thorn E; Amiri S; Socias ME; Lutz R; Amram O Am J Drug Alcohol Abuse; 2023 Sep; 49(5):597-605. PubMed ID: 37433122 [No Abstract] [Full Text] [Related]
10. Patient perspectives on community pharmacy administered and dispensing of methadone treatment for opioid use disorder: a qualitative study in the U.S. Wu LT; John WS; Mannelli P; Morse ED; Anderson A; Schwartz RP Addict Sci Clin Pract; 2023 Aug; 18(1):45. PubMed ID: 37533071 [TBL] [Abstract][Full Text] [Related]
11. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19. Brothers S; Viera A; Heimer R J Subst Abuse Treat; 2021 Dec; 131():108449. PubMed ID: 34098303 [TBL] [Abstract][Full Text] [Related]
12. Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial. Wu LT; John WS; Morse ED; Adkins S; Pippin J; Brooner RK; Schwartz RP Addiction; 2022 Feb; 117(2):444-456. PubMed ID: 34286886 [TBL] [Abstract][Full Text] [Related]
13. Increased flexibility in methadone take-home scheduling during the COVID-19 pandemic: Should this practice be incorporated into routine clinical care? Trujols J; Larrabeiti A; Sànchez O; Madrid M; De Andrés S; Duran-Sindreu S J Subst Abuse Treat; 2020 Dec; 119():108154. PubMed ID: 33032860 [TBL] [Abstract][Full Text] [Related]
14. Loss, liberation, and agency: Patient experiences of methadone treatment at opioid treatment programs during the COVID-19 pandemic. López-Castro T; Jakubowski A; Masyukova M; Peterson M; Pierz A; Kodali S; Arnsten JH; Starrels JL; Nahvi S J Subst Use Addict Treat; 2024 Feb; 157():209235. PubMed ID: 38061636 [TBL] [Abstract][Full Text] [Related]
16. Impact of COVID-19-related methadone regulatory flexibilities: views of state opioid treatment authorities and program staff. Mitchell SG; Jester J; Gryczynski J; Whitter M; Fuller D; Halsted C; Schwartz RP Addict Sci Clin Pract; 2023 Oct; 18(1):61. PubMed ID: 37848970 [TBL] [Abstract][Full Text] [Related]
17. Changes in methadone take-home dosing before and after COVID-19. Amram O; Amiri S; Thorn EL; Lutz R; Joudrey PJ J Subst Abuse Treat; 2022 Feb; 133():108552. PubMed ID: 34304950 [TBL] [Abstract][Full Text] [Related]
18. Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study. Oviedo-Joekes E; MacDonald S; Boissonneault C; Harper K Subst Abuse Treat Prev Policy; 2021 Mar; 16(1):22. PubMed ID: 33673847 [TBL] [Abstract][Full Text] [Related]
19. Shifting Medication Treatment Practices in the COVID-19 Pandemic: A Statewide Survey of Pennsylvania Opioid Treatment Programs. Krawczyk N; Maniates H; Hulsey E; Smith JS; DiDomenico E; Stuart EA; Saloner B; Bandara S J Addict Med; 2022 Nov-Dec 01; 16(6):645-652. PubMed ID: 35165225 [TBL] [Abstract][Full Text] [Related]
20. Patient experiences of methadone treatment changes during the first wave of COVID-19: a national community-driven survey. Brothers S; Palayew A; Simon C; Coulter A; Strichartz K; Voyles N; Vincent L Harm Reduct J; 2023 Mar; 20(1):31. PubMed ID: 36894968 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]